Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma
Kevin Reyes, Yen‐Chun Liu, Chiung‐Yu Huang, et al.
Blood Advances (2024) Vol. 8, Iss. 9, pp. 2207-2216
Open Access | Times Cited: 12

Showing 12 citing articles:

Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial
Jieyun Xia, Qian Sun, Dian Zhou, et al.
The Lancet Haematology (2025)
Closed Access | Times Cited: 1
Charting the Course: Sequencing Immunotherapy for Multiple Myeloma
Meera Mohan, Oliver Van Oekelen, Othman Salim Akhtar, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 7
Strategies for salvage therapy post CAR-T therapy failure in refractory/relapsed multiple myeloma patients
Chao Min, Xiong Zhong, Yue Cui, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Sequence not salvage
Douglas W. Sborov, Gliceida Galarza Fortuna, Patrick Hayden
British Journal of Haematology (2024) Vol. 204, Iss. 5, pp. 1590-1592
Open Access | Times Cited: 2
Mechanisms and salvage treatments in patients with multiple myeloma relapsed post-BCMA CAR-T cell therapy
Bingjie Fu, Rui Liu, Gongzhizi Gao, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Bispecific antibodies for the treatment of hematologic malignancies: The magic is T-cell redirection
Geoffrey Shouse
Blood Reviews (2024), pp. 101251-101251
Closed Access | Times Cited: 2
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy
Maximilian Merz, Danai Dima, Hamza Hashmi, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Bispecific antibody and chimeric antigen receptor (CAR) modified T-cell in the treatment of multiple myeloma: where do we stand today?
Xiang Zhou, K. Martin Kortuem, Leo Rasche, et al.
La Presse Médicale (2024), pp. 104265-104265
Open Access | Times Cited: 2
Advances in research on factors affecting chimeric antigen receptor T‐cell efficacy
Delian Zhou, Xiaojian Zhu, Yi Xiao
Cancer Medicine (2024) Vol. 13, Iss. 11
Open Access | Times Cited: 1
Advancements in Bispecific Antibodies for Multiple Myeloma: What's New and What Lies Ahead
Tarek H. Mouhieddine, Bruno Almeida Costa, Joshua Richter
Seminars in Hematology (2024)
Closed Access | Times Cited: 1
Allogeneic stem cell transplantation in multiple myeloma: is there still a place?
Carmine Liberatore, Francesca Fioritoni, Mauro Di Ianni
Frontiers in Oncology (2024) Vol. 14
Open Access
Bispecific T-Cell Engagers: Sequencing, BCMA, GPRC5D, and Resistance
Amrita Krishnan
Clinical Lymphoma Myeloma & Leukemia (2024) Vol. 24, pp. S98-S99
Closed Access
Page 1

Scroll to top